Literature DB >> 3946458

A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study.

W P Castelli, K Anderson.   

Abstract

In the Framingham Study, coronary heart disease developed in every fifth man and every 17th woman by the age of sixty. The level of total cholesterol proved to be an excellent predictor of coronary heart disease in those aged less than 50 years. However, in those aged over 50 years, more accurate predictors of coronary heart disease risk were serum lipoprotein measurements, including low-density lipoproteins, very-low-density lipoproteins, very-low-density lipoprotein triglycerides, and high-density lipoproteins. Both low-density and very-low density lipoproteins have a linear association with coronary heart disease. On multivariate analysis, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol are independently related to coronary heart disease risk in both sexes. In women, but not in men, very-low-density lipoprotein cholesterol or the triglyceride level is an independent risk factor on multivariate analysis. By likelihood ratio analysis, high-density lipoprotein is shown to be the most powerful single factor for predicting coronary heart disease risk in both sexes relative to the lipid fractions. It appears that one of the most reliable profiles in this regard is the ratio of total cholesterol to high-density lipoprotein cholesterol. However, a special constellation of elevated triglycerides, low high-density lipoprotein levels, and "normal" cholesterol values should no longer be overlooked in assessing coronary heart disease risk. Both systolic and diastolic blood pressures are also related to risk of coronary heart disease in a linear fashion: the higher the level of pressure, the greater the incidence of coronary heart disease. Blood pressure and serum cholesterol are correlated with an r factor of 0.12, suggesting that those with higher blood pressure values tend to have higher serum cholesterol levels. Most physicians agree that treatment is advisable in those with cholesterol levels above 300 mg/dl; some believe therapy is necessary in those with levels of more than 250 mg/dl. Few realize that half of the patients in whom coronary heart disease will eventually develop have cholesterol values under 250 mg/dl. The National Institutes of Health Consensus Development Conference on Lipid Lowering has recommended that cholesterol levels be reduced to 200 mg/dl in all persons. Practicing physicians argue that coronary heart disease does not develop in most patients with cholesterol levels between 200 and 250 mg/dl. The problem lies in deciding which patients with these cholesterol levels actually have a lipid abnormality.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3946458     DOI: 10.1016/0002-9343(86)90157-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  44 in total

Review 1.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

2.  First line treatment in hypertension.

Authors: 
Journal:  BMJ       Date:  1991-01-12

3.  Total and high-density lipoprotein cholesterol measurements. Hazards in clinical interpretation.

Authors:  A U Rivin
Journal:  West J Med       Date:  1989-09

Review 4.  Measuring selection in contemporary human populations.

Authors:  Stephen C Stearns; Sean G Byars; Diddahally R Govindaraju; Douglas Ewbank
Journal:  Nat Rev Genet       Date:  2010-08-03       Impact factor: 53.242

Review 5.  Perindopril safety and tolerance in at-risk patients.

Authors:  S Brichard; A E Lambert
Journal:  Drugs       Date:  1990       Impact factor: 9.546

6.  Hypertension and combinations of cardiovascular risk factors. An epidemiologic case-control study in an adult population in Guadeloupe (FWI).

Authors:  L Foucan; J Bangou-Brédent; D K Ekouévi; J Deloumeaux; J E Roset; P Kangambega
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

7.  Effects of dicentrine on haemodynamic, plasma lipid, lipoprotein level and vascular reactivity in hyperlipidaemic rats.

Authors:  S M Yu; Y F Kang; C C Chen; C M Teng
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

8.  Lipoprotein (a), low-density, intermediate-density lipoprotein, and blood pressure in a young male population.

Authors:  A Steinmetz; A Kirklies; G Schlosser; W Cassel; J H Peter; K Ehlenz; J R Schäfer; P V Wichert; H Kaffarnik
Journal:  Clin Investig       Date:  1993-02

9.  Plasma lipids and lipoproteins and essential hypertension.

Authors:  M Flesch; A Sachinidis; Y D Ko; K Kraft; H Vetter
Journal:  Clin Investig       Date:  1994-12

10.  Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients.

Authors:  Juergen Graessler; Dominik Schwudke; Peter E H Schwarz; Ronny Herzog; Andrej Shevchenko; Stefan R Bornstein
Journal:  PLoS One       Date:  2009-07-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.